Maintenance Therapy Improves AML Outcomes Regardless of MRD Status or Consolidation Cycles

New data from the phase III QUAZAR AML‐001 trial confirm the benefits of maintenance therapy with oral azacitidine in acute myeloid leukemia regardless of patients' minimal residual disease status or the number of consolidation cycles prior to study enrollment.